Logo

Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product- Qutenza (capsaicin)

Share this
Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product- Qutenza (capsaicin)

Grunenthal Acquires Averitas Pharma for its Peripheral Neuropathic Pain Product- Qutenza (capsaicin)

Shots:
  • Grunenthal acquired Averitas Pharma in all stocks transaction- gained the commercialization rights for Qutenza
  • The focus of the acquisition is to expand and strengthen its footprints in the markets of US
  • Qutenza (8% capsaicin) is an analgesic and is approved by the US FDA & EU for postherpetic neuralgia (PHN) & peripheral neuropathic pain indication in adults respectively
Ref: Grunenthal | Image: Glarus24

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions